Real-time Stock quotes, portfolio, LIVE TV and more.
Aug 09, 2012, 09.57 AM IST
Pharmaceutical company Ranbaxy Labs' revenues are seen going up by 30% YoY to Rs 2,727 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to go up by 117% YoY to Rs 395 crore in the April-June quarter.
By Ekta Batra, Research Analyst at CNBC-TV18
Pharmaceutical company Ranbaxy Labs is set to declare its second quarter numbers for the calendar year 2012 on Thursday. Analysts on an average expect the profit after tax is likely to be at Rs 235 crore as against Rs 243 crore in a year ago period and Rs 1,247 crore in the previous quarter.
The company has reported net forex gain of Rs 93 crore in the second quarter of CY11 and Rs 344 crore in the first quarter of CY11.
Revenues are seen going up by 30% YoY to Rs 2,727 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to go up by 117% YoY to Rs 395 crore in the April-June quarter.
Operating profit margin is likely to increase 580 basis points to 14.5% versus 8.7% during the same period.
Investors should watch out for update on USFDA action plan, forex gain/loss and the impact of Lipitor generic this quarter.
Also watch out for base business - All other geographies except for US & India disappointed last quarter.
In constant currency, Africa was flat while Latin America, Eastern Europe and CIS declined YoY.
Domestic business was strong last quarter, which rose by 13% to Rs 430 crore in Q1CY12.
Analysts expect the domestic business to improve in the June quarter as well due to anti-infectives.
Action in Ranbaxy Laboratories
May 23 2013, 16:33
- in Asian markets
May 23 2013, 09:33
- in Technicals